Pharma: Life styles matter - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Pharma: Life styles matter

Sep 6, 2004

Lifestyle drugs have taken the centre stage in the last few years. To put things in perspective, for the first time in 2003, CVS (cardiovascular) drugs overtook anti-ulcerants as the largest therapeutic class worldwide. But India is yet to catch up! Lifestyle drugs are the basically medicines used to cure diseases that are linked to stress, urbanization, changing diet pattern and lifestyle of high-income level population. Major drugs in this segment are anti-diabetes drugs, cardiovascular drugs, gentio-urinary and sex hormones drugs, CNS drugs, anti-depressants and psychiatry.

India continues to be a market where anti-infectives continue to lead the therapeutic drug class with about 16% market share. Having said that, lifestyle drugs have been the key growth driver for the domestic pharma industry and this is the reason Indian companies have started focusing on lifestyle drugs with slew of launches in the last few months.

Among the various therapeutic segments, respiratory and anti-infectives (non lifestyle drugs) fuelling growth till FY02. But, as is evident from the table below, there has been a slowdown in these segments. At the same time, impressive growth in the life style drug segment has brought a new lease of life. This can be attributed to the changing lifestyle and increasing urbanization in India. The following table shows the market growth rates for FY04 and FY03.

Therapeutic Segments Growth:
Therapeutic Segment Market Growth Rate FY03 Market Growth Rate FY04
Respiratory 5.6% 9.0%
Anti-Infectives -0.2% 5.0%
Lifestyle Drugs:
Anti-Diabetics 20.3% 11.6%
Cardio Vascular Segments 12.4% 17.2%
CNS 13.4% 8.9%

As said earlier, internationally, lifestyle drugs are major contributor to the pharma industry and India is also moving in the same direction. Also, the fact that the higher-income group drives the demand for lifestyle drugs, it is not price sensitive in nature. Thus, a major portion of the growth of these drugs is coming from value rather than volume. Consequently, margins are also high.

Rising demand and relatively better margins have resulted in Indian companies concentrating more on lifestyle drugs in the recent past. For instance, in case of Nicholas Piramal, the share of lifestyle drugs in its portfolio increased by about 6% in the last two years (24% in FY02 to 29% in FY04). In case of Sun Pharma, the three segments of lifestyle drugs accounted for 61% of its domestic prescription sales in FY04.

Going forward, we may see that the contribution from lifestyle drugs for many companies growing at a faster rate than traditional therapeutic segments. Companies like Cipla and Ranbaxy, who have been big players the traditional segments, have launched several products in the lifestyle category in recent times. While we expect higher benefits from such an industry transition in the medium-term, as competition increases, margins will be squeezed.


Equitymaster requests your view! Post a comment on "Pharma: Life styles matter". Click here!

  

More Views on News

LAURUS LABS LTD Share Price Down by 5%; BSE HEALTHCARE Index Down 1.0% (Market Updates)

Sep 24, 2020 | Updated on Sep 24, 2020

LAURUS LABS LTD share price is trading down by 5% and its current market price is Rs 1,347. The BSE HEALTHCARE is down by 1.0%. The top gainers in the BSE HEALTHCARE Index are APOLLO HOSPITALS (up 5.2%) and SYNGENE INTERNATIONAL (up 3.5%). The top losers is LAURUS LABS LTD (down 5.3%)..

NARAYANA HRUDAYALAYA LTD Share Price Down by 8%; BSE HEALTHCARE Index Down 1.6% (Market Updates)

Sep 24, 2020 | Updated on Sep 24, 2020

NARAYANA HRUDAYALAYA LTD share price is trading down by 8% and its current market price is Rs 302. The BSE HEALTHCARE is down by 1.6%. The top gainers in the BSE HEALTHCARE Index is SANOFI INDIA (up 1.6%). The top losers is NARAYANA HRUDAYALAYA LTD (down 7.8%)..

More Views on News

Most Popular

How the 8-Year Cycle Can Help Identify Multibaggers (Fast Profits Daily)

Sep 11, 2020

This is how you can apply the greed and fear cycle in the market to pick stocks.

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

This Could Be the Best September for Auto Stocks (Profit Hunter)

Sep 11, 2020

Here's why I think this month could be a great for auto stocks.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Sep 24, 2020 (Close)

COMPARE COMPANY

MARKET STATS